Status:
UNKNOWN
HRD and Resistance to PAPPi in EOC Patients
Lead Sponsor:
Lei Li
Conditions:
Epithelial Ovarian Cancer
Homologous Recombination Deficiency
Eligibility:
FEMALE
18+ years
Brief Summary
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in p...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Pathological confirmation of epithelial ovarian cancer
- With available tumor tissues
- Given consents to participate the study
- With detailed follow-up outcomes
Exclusion
- Not meeting all of the inclusion criteria
- Declining to accept PARPi as maintenance therapy after the major treatment for cancer
Key Trial Info
Start Date :
March 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 26 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05310370
Start Date
March 26 2022
End Date
March 26 2025
Last Update
April 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730